Autres langues Santen Pharmaceutical Co., Ltd.

Actions

4536

JP3336000009

Temps Différé Japan Exchange Autres places de cotation 04:17:26 08/05/2024			Varia. 5j.	Varia. 1 janv.
1 544 ^JPY	+1,11%		+1,38%	+9,89%

26/03	Santen Pharmaceutical annule 12 millions d'actions d'autocontrôle	MT
25/03	Santen annonce la redésignation d'Akira Kurokawa en tant que directeur du conseil d'administration et président, à partir du 1er avril 2024.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Santen Pharmaceutical : and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis	07/05
Santen Pharmaceutical : and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL	17/04
Santen Pharmaceutical : Positioned for Further Growth in China Following Completion of Vision Park	16/04
Santen Pharmaceutical : obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis	26/03
Santen Pharmaceutical to Cancel 12 Million Treasury Shares	26/03
Santen Pharmaceutical : Announces Change of Representative Director of the Board	25/03
Santen Pharmaceutical : Announces Cancellation of Treasury Shares	25/03
Santen Pharmaceutical : Announces Completion of Share Buyback	25/03
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	25/03
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	25/03
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.	22/03
Santen Pharmaceutical : Announces Status of Share Buyback	01/03
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	09/02
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	08/02
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	08/01
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	05/01
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	04/12
Santen Pharmaceutical : Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension	17/11
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	08/11
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	07/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Santen Pharmaceutical Co., Ltd.

Actions

4536

JP3336000009

Autres langues

Filtres